# Title page

**Title**: Risk of complications and mortality following recurrent and non-recurrent *Clostridioides* (*Clostridium*) *difficile* infection: a retrospective, observational, database study in England

**Authors**: David A Enoch1\*, Tarita Murray-Thomas2, Nicholas Adomakoh3, Daniel Dedman2, Areti Georgopali3, Nick Francis4†, Andreas Karas3

**Affiliations**:1Public Health England, Addenbrooke’s Hospital, Cambridge, UK; 2Clinical Practice Research Datalink, London, UK; 3Astellas Pharma Europe Ltd, Chertsey, UK; 4Division of Population Medicine, Cardiff University, Cardiff, UK

†Current affiliation: School of Primary Care, Population Sciences and Medical Education, University of Southampton, UK

**Target journal**: *J Hosp Infect*

**Word count** (max. 4000 words; each figure and/or table counts as 200 words towards the total; not including author declaration): 3408 + 3 tables + 2 figures = 4408

**Structured summary** (max. 250 words):248

**Number of proposed figures** (no maximum given): 2 (counted as 400 words in total)

**Number of proposed tables** (no maximum given): 3(counted as 600 words in total)

**References** (no maximum given): 51

**Online supplementary material: Supplementary** methods, Tables A.I–A.III, Figure A.1

**Running title** (max. 40 characters including spaces): Outcomes after *C. difficile* infection [38 characters including spaces]

\***Corresponding author**:

**Name**: David Enoch

**Address**: Clinical Microbiology & Public Health Laboratory, National Infection Service, Public Health England, Box 236, Addenbrookes Hospital, Hills Road, Cambridge, CB2 0QW

**Tel**.: 01223 257035

**Email**: david.enoch@addenbrookes.nhs.uk

# Structured summary

**Word count**: 248 / 250 words

**Background**: *Clostridioides difficile* infection (CDI) increases the risk of complications and mortality. We assessed the magnitude of these outcomes in a large cohort of English patients with initial and recurrent CDI.

**Aim**: To compare the risk of complications and all-cause mortality, within 12 months, among hospitalized patients ≥18 years old with hospital-associated (HA-) CDI and recurrent CDI.

**Methods**: Patients with HA-CDI during 2002–2013 were identified using inpatient hospital data linked to primary care and death data. Each HA-CDI case was frequency matched to two hospitalized patients without CDI on age group, sex, calendar year of admission, admission method and number of hospital care episodes. A second CDI episode starting on Days 13−56 was defined as recurrence. Risks of mortality and complications at 12 months were analysed using Cox proportional hazard models.

**Findings**: We included 6,862 patients with HA-CDI and 13,724 without CDI. Median age was 81.0 (71.0–87.0). Patients with HA-CDI had more comorbidities than those without CDI, and significantly higher risks of mortality (adjusted hazard ratio (95% confidence interval) 1.77 (1.67–1.87)) and complications (1.66 (1.46–1.88)) within 12 months from hospital admission. Of those with HA-CDI, 1,140 (16.6%) experienced CDI recurrence. Patients with recurrent versus non-recurrent CDI also had significantly increased risk of mortality (1.32 (1.20−1.45)) and complications (1.37 (1.01−1.84)) in the 12 months from the initial CDI.

**Conclusions**: HA-CDI (versus no CDI) and recurrent CDI are both associated with significantly higher risks of complications or death within 12 months of the initial CDI episode.

**Keywords** (max. 6; to be derived from the summary): *Clostridioides difficile* infection, recurrence, mortality, complications

# Abbreviations

[To contain only non-standard abbreviations]

|  |  |
| --- | --- |
| APC | Admitted Patient Care |
| CA | Community associated |
| CDI | *Clostridioides (Clostridium) difficile* infection |
| CPRD | Clinical Practice Research Datalink |
| GOLD | GP Online Data |
| HA | Hospital associated |
| HES | Hospital Episode Statistics |
| IBD | Inflammatory bowel disease |
| ICD-10 | International Classification of Diseases 10th revision |
| IMD | Index of Multiple Deprivation |
| ONS | Office for National Statistics |

# Introduction

*Clostridioides* (formerly *Clostridium*) *difficile* is a Gram-positive, spore-forming, anaerobic bacillus that is predominantly a nosocomial pathogen [1]. Traditional risk factors for infection include older age, hospital duration, prolonged use of antimicrobials, and use of immunosuppressive or gastric-suppressive medications [2–7]. Other secondary risk factors include a history of inflammatory bowel disease (IBD), cystic fibrosis and diabetes [8].

*C. difficile* infection (CDI) is a major cause of morbidity and mortality in hospitalized patients [9,10]. Several studies have reported increased toxic megacolon, perforation and sepsis among patients with CDI [3,11–13]. Significantly higher risks of all-cause mortality have also been observed in the USA [14] and Europe [15,16]. In the UK, one study using surveillance data from Scotland estimated an almost three-fold increase in 30-day mortality [17] and another reported a 50% increased risk of death up to 5–8 years after hospital admission among patients with CDI at an English teaching hospital [18]. The incidence of CDI recurrence ranges from 11% to 33%, and recurrence is also associated with higher patient mortality and complication rates [19–21], although lower mortality rates have been reported among patients with recurrent CDI compared to first episodes [22].

Although several previous studies examined complications and mortality rates among patients with CDI, they were sometimes limited by small sample sizes [16,18], focused on either in-hospital [23,24] or post-discharge mortality [21], or did not include clinical information from outside the hospital setting [16–18,25]. Some studies were also restricted to populations from specialist centres or other clinical settings that may not be representative of wider groups of patients with CDI [20,21].

To overcome these issues, we conducted a frequency-matched, longitudinal, retrospective cohort study using data from hospitalized patients linked to a primary care database and a national death registry, to assess the risk of mortality and complications among patients with hospital-associated (HA)-CDI versus no CDI, during 1st January 2002 to 31st December 2013. We separately assessed the risk of mortality and complications in patients with recurrent CDI versus patients with non-recurrent CDI.

# Methods

## Data sources

Data were extracted from the UK Clinical Practice Research Datalink (CPRD GOLD), a longitudinal primary care electronic database of anonymized patient records, collected from a sample of general practices in the UK. Analyses were restricted to 380 practices in England with individual record linkage to Hospital Episode Statistics (HES) Admitted Patient Care (APC) data, which comprise admission and discharge dates plus information on clinical diagnoses and procedures collected from English hospitals [26]; the Office for National Statistics (ONS) database, which holds data on the date and cause of death [27]; and/or the Index of Multiple Deprivation (IMD), which combines a number of economic and social indicators into a single deprivation score based on area of residence [28]. In the case of the IMD, which ranks areas relative to one another from 1 to 32,844, the raw scores were categorized into quintiles, with 1 being the least deprived and 5 the most deprived. Analyses of primary outcomes were restricted to patients in CPRD GOLD eligible for linkage to both HES APC and ONS death data. For secondary outcomes where death was not evaluated, patients were required to be eligible for linkage to HES and IMD data only.

## Study population

The risk of mortality and complications among hospitalized patients with a first episode of HA-CDI was compared with frequency-matched (1:2) hospitalized patients without CDI. Recurrence was evaluated among the sub-cohort of patients with a first episode of HA-CDI. Only patients with ≥6 months of follow up during the study period were eligible for inclusion.

### CDI case selection

Cases were patients with a diagnosis of HA-CDI recorded during 1st January 2002 – 31st December 2013. Eligible patients were aged ≥18 years at index hospital admission with ≥1 diagnosis of HA-CDI documented during their first or second episode of hospital care (periods during which a patient was under the care of a particular consultant [29]) only. Pregnancy-related admissions, between-hospital transfers and patients with a first CDI occurrence recorded in hospital care episode ≥3 were excluded.

Cases were ascertained based on ICD-10 (International Classification of Diseases 10th revision) A04.7 *‘Enterocolitis due to Clostridium difficile’* or related codes, recorded in HES APC data. HA-CDI was defined using a modified algorithm from Jen et al. [30], and was specified as a primary diagnosis of CDI (CDI recorded in the first hospital care episode and in the first diagnosis order) *and* a history of hospitalization within the preceding 4 weeks, *or* CDI recorded as a secondary diagnosis during the first or second episode of a hospital stay of >2 days (**Figure A.1**, online supplementary material). As the exact dates of clinical onset are not recorded in HES, the index date of the CDI episode was defined as the start of the care episode in which the CDI was recorded.

### Control group selection

Cases were frequency matched to two hospitalized patients without CDI (unexposed patients) through random selection. Potential controls with CDI or diarrheal illness in HES or primary care up to 90 days prior to their index admission were excluded. Unexposed patients were selected to reflect the distribution of the case pool on the following parameters: calendar year of diagnosis, sex, age group, index admission method (emergency or non-emergency) and the number of hospital care episodes (one or more). The matched hospital care episode for the unexposed patients was randomly sampled to reflect the distribution of episodes in which CDI was recorded. The index date was defined as the start of the randomly selected care episode.

Recurrence of CDI was defined as a second CDI episode documented on Days 13−56 inclusive, after the index episode. The date of CDI recurrence was defined as the start of the care episode in which the diagnosis was made. Otherwise, patients with a single record of CDI documented during the study period, with all CDI events recorded within 12 days of their first CDI episode or with their second CDI event recorded after Day 56 were included in the non-recurrent CDI cohort. Follow-up time for these patients was censored at the date of their second CDI diagnosis.

## Outcomes

The primary outcome was time to all-cause mortality, up to 12 months, as evidenced by a record of death in the ONS mortality record. Only mortality events recorded during the patient’s registration period at the practice were included. Secondary outcomes were the time to first complication and time to the combined endpoint of complications or death, up to 12 months. Complications included ulcerative pancolitis, megacolon, intestinal perforation, toxic gastroenteritis/colitis, colectomy, renal failure and sepsis, and were identified using ICD-10 codes in HES or ONS mortality data, Read Codes in primary care, and/or Office of Population Censuses and Surveys procedure codes in hospital (**Table A.I**, online supplementary material). Admission to augmented or critical care for any reason during the follow-up period was also classed as a complication. Events occurring prior to the index date were excluded.

## Study size

Assuming a cumulative risk of 21.5% for 1-year mortality among patients without diarrhoea and unexposed to CDI [31], 1,571 patients with and without CDI would provide 90% power to detect a statistically significant difference between groups at a two-sided significance level of 0.05, if the real difference in 1-year mortality was ≥5%. Using a 1-year mortality rate of 15.3% among patients with non-recurrent CDI [32], 1,228 patients with and without recurrent CDI would provide 90% power to detect a statistically significant difference between groups at a two-sided significance level of 0.05, if the real difference in mortality was ≥5%. We elected to use a ratio of 1:2 of cases to controls for any incremental power that this might add.

## Statistical analysis

Baseline characteristics were summarized using Chi-squared tests, t-tests and Mann–Whitney U tests, where appropriate. Kaplan-Meier analysis was initially used to estimate the cumulative incidence function of time to mortality or complications up to 12 months. Cox proportional hazard regression models, with backward stepwise selection of candidate variables, were fitted to compare hazards of endpoints during the outcome periods. To assess the impact of immortal time bias [33], Cox regression models were alternatively specified with time-fixed or time-dependent covariates. For the comparison of HA-CDI versus no CDI, two models were used: CDI was specified as either a time-dependent or time-fixed covariate, the index date of CDI was set as the start of the CDI episode, and follow up was from either hospital admission or from the start of the CDI episode. The comparison of recurrent versus non-recurrent CDI used four different models, with CDI specified as either a time-dependent or time-fixed covariate; the index date of recurrent CDI specified as either the start of the recurrent episode or final CDI status; and follow up from either the episode start of the index CDI, Day 13 (the start of the recurrence risk window) or Day 57 (the end of the recurrence risk window). Tests for proportional hazards were undertaken visually using log–log plots and statistically by assessing Schoenfeld’s residuals. Hazard ratios (HR) with 95% confidence intervals (CIs) were reported and two-sided *P*-values were calculated using the Wald test.

Adjustment factors measured at cohort entry using primary care and/or HES data included age in years, sex, body mass index, smoking history, alcohol use, history of comorbidities, drug therapies and socioeconomic deprivation category (**online supplementary material**). To further assess the robustness of our findings, we conducted sensitivity analyses taking the midpoint of the hospital care episode as the CDI index date (**Tables A.II** and **A.III**, online supplementary material). The end of follow up was defined as the earliest of the following: practice last collection date, patient deregistration date, date of complication diagnosis or death, end of HES data collection, end of ONS mortality data collection, or study end.

All analyses were performed using STATA version 14.

## Ethics

CPRD has ethical approval for the collection and use of pseudonymized primary care records and linked data from the Health Research Authority Research Ethics Committee (reference number: 05/MRE04/87). The study was approved by the Independent Scientific Advisory Committee of the Medicines and Healthcare products Regulatory Agency, under protocol number 14\_187A3.

# Results

## Patient populations

Between 1st January 2002 and 31st December 2013, 5 552 368 patients registered in CPRD GOLD were eligible for linkage to HES and ONS data (**Figure 1**). Following the implementation of inclusion and exclusion criteria, 6862 patients met our definition of HA-CDI (**Figure 1**) and were matched to 13 724 hospitalized patients without CDI.

## Demographic and clinical characteristics

*Patients with HA-CDI versus no CDI*

The median age (interquartile range) of all participants was 81.0 (71.0–87.0) years; females comprised 59.0% (12 141/20 586) of patients. Compared with patients with no CDI, patients with HA-CDI had higher healthcare service use in the 12 months prior to CDI diagnosis, more recorded comorbidities (including a history of IBD and diabetes mellitus), and more antibiotics prescribed in the 90 days prior to admission (**Table I**). Higher prior use of proton-pump inhibitors and more admissions to augmented or intensive care were also observed (**Table I**).

*Patients with recurrent CDI versus non-recurrent CDI*

Within the HA-CDI sub-cohort, 16.6% (1140/6862) of patients had a recurrent CDI episode during Days 13–56. Notably, patients with recurrent CDI had a longer index hospital stay and were more likely to have had an emergency index hospital admission (**Table I**)**.** A history of hypertension, renal disease, moderate/severe liver disease and use of lipid-lowering therapy were also more commonly documented among those with recurrent CDI (**Table I**). A history of malignant cancer (up to 5 years prior to the index CDI diagnosis) and dementia were more prevalent in the non-recurrent CDI group (**Table I**).

## Twelve-month risk of death or complications

### Patients with HA-CDI versus no CDI

There were 3427/6862 (49.9%) and 4146/13 724 (30.2%) deaths among patients with and without CDI, respectively, at 12 months from the initial hospital care episode (*P*<0.001) (**Table II**). In the time-dependent and time-fixed analyses, the adjusted HR for death among patients with HA-CDI versus no CDI were 1.77 (95% CI: 1.67, 1.87) and 1.55 (95% CI: 1.47, 1.64), respectively (**Table III**).

Similarly, significantly more patients with HA-CDI experienced complications up to 12 months following index hospital admission, compared with patients with no CDI (*P*<0.001) (**Table II**). The adjusted HR from time-dependent analysis for complications in the group of patients with HA-CDI versus no CDI was 1.66 (95% CI: 1.46, 1.88) (**Table III**).

### Patients with recurrent versus non-recurrent CDI

There were 564 (49.5%) and 2737 (47.8%) deaths among patients with recurrent and non-recurrent CDI, respectively, at 12 months from the initial hospital care episode (**Table II**). When evaluating the risk of death from the start of initial CDI episode, the incidence of mortality at ≤30 days and ≤90 days was significantly lower in patients with recurrent CDI and the difference in mortality at ≤365 days was not significant (**Table II**). Adjusted time-fixed analyses showed a seemingly implausible protective effect of recurrence on 12-month mortality (HR: 0.88, 95% CI: 0.80, 0.96) (**Table III**). When immortal time was correctly classified (**Figure 2)**, 12-month survival was higher in those with non-recurrent CDI versus recurrent CDI (HR: 1.32, 95% CI: 1.20, 1.45) (**Table III**).

The incidence of complications (excluding death) up to 90–365 days from the start of the initial care episode was significantly higher (*P*≤0.005) in patients with recurrent CDI (**Table II**). The adjusted HR for complications excluding death, up to 12 months from the start of the initial care episode, was 1.37 (95% CI: 1.01, 1.84) (**Table III**).

Results of further sensitivity analyses, with outcomes assessed from the midpoint of the initial hospital care episode, are included in **Tables A.II–A.III** (online supplementary material).

# Discussion

We conducted a retrospective study of patients hospitalized in England with a first episode of CDI and observed that the risk of 12-month mortality and complications was significantly higher compared with matched hospitalized patients with no evidence of CDI, a finding supported by previous research [14,17,23,34–36]. Interestingly, in a study of CDI in Scotland [17], the 30-day all-cause mortality rate of 17.5% was similar to the rate we observed in England (16.3%), despite the use of differing time periods and database methodology. Additionally, mortality and complications were increased significantly in patients with recurrent CDI compared with non-recurrent CDI, findings which align with earlier research in the USA [19,21]. It is, however, important to note that our study population was older and had more comorbidities than some populations studied in North America [19,20,35] and Europe [31]. This age difference is similar to findings from studies of fidaxomicin for the treatment of CDI, in which the median age in the UK was 70–81 years [37] whilst in North America and Europe, the mean age was 61–63 years [38,39].

We also found a higher frequency of risk factors recorded among CDI cases: more comorbidities, more patients with prior prescriptions of antibiotics and/or proton-pump inhibitors, a greater incidence of hospitalization within the previous 12 months, and significantly higher use of augmented or intensive care; these results are also consistent with previous studies [40–44]. The finding that lipid-lowering drugs had a statistically significant risk for CDI is novel and requires further study, although the difference is small. Among patients with CDI, we also found higher rates of hypertension, renal disease, moderate-to-severe liver disease, inflammatory bowel disease and malignant cancer, compared with patients with no CDI. Conversely, the incidence of inflammatory bowel disease was not significantly higher among patients with recurrent versus non-recurrent CDI, and the rate of malignant cancer was significantly higher in the non-recurrent CDI group. Hypertension, renal disease, liver disease and malignant cancer have been found to be associated with recurrence in previous studies [45–49]. The reason for the higher rate of malignant cancer among patients with non-recurrent CDI in our study is not explainable and may be due to the methodology used in the definition of the recurrence window, which is a particular challenge in this type of large database study, or the immortal time bias already described.

Strengths of this study include its use of objective death data from the ONS mortality registry to confirm vital status and its inclusion of both primary and secondary care data in risk factor and covariate definitions. This is likely to have increased outcome ascertainment in our study, as well as the accuracy and completeness of data on baseline characteristics and covariates. Our study also provides insights on the risk of outcomes in both the early and later periods following CDI diagnosis by taking account of all deaths recorded up to 12 months.

Sensitivity analyses to assess the robustness of our findings offered insights into some of the methodological issues involved in the use of real-world data for infectious disease epidemiology. For example, comparison of the mortality incidence between recurrent and non-recurrent CDI groups showed that patients with recurrent CDI had significantly lower mortality up to 90 days from the start of initial hospitalization, than those with non-recurrent CDI. This can be explained by the effects of immortal time bias: by definition, patients with recurrent CDI would need to survive long enough to experience a second CDI episode 13–56 days after the first. Similarly, our time-fixed analyses showed that recurrent CDI was protective regarding the 12-month risk of death. However, this implausible benefit was invalidated once immortal time was correctly classified by following patients from the start of the recurrence window in a time-dependent analysis or from the end of the recurrence risk window in a time-fixed analysis. In contrast with mortality, the occurrence of a non-fatal complication does not preclude a recurrent CDI episode, and the 12-month risk of complications were thus more frequently observed in the group with recurrent CDI versus non-recurrent CDI, regardless of the analyses used.

One limitation of this study is that some patients in our primary and secondary analyses may have been incorrectly classified as CDI-positive due to the lack of laboratory confirmation of infection. Secondly, a precise onset or CDI diagnosis date was not available for either the primary or recurrent episode of CDI, as clinical data in the HES database are grouped into episodes of care rather than presented as separate encounters [29]. This limitation may have led to misclassification of initial CDI or recurrence status, and/or an inaccurate time to event in the survival analysis. Given this important limitation, throughout our study we selected analysis parameters that would provide more conservative estimates of the effect of CDI exposure on outcomes.

Thirdly, the CPRD GOLD and HES databases lack information on some important factors, such as disease severity, infection strain, metabolic changes associated with CDI, severity of comorbidities and prescribing in the secondary care setting, which may introduce residual confounding. It is, however, reasonable to assume that some factors may be non-differentially distributed between exposure and comparison groups. Additionally, location and organizational information such as hospital provider codes or hospital ward are not routinely available in the HES data collected by CPRD, to minimize the potential risk of patient re-identification. Hospital and ward information was therefore not used as a matching parameter for cases and controls. Instead, we opted to take account of whether patients were admitted for emergency or elective procedures as a proxy for the severity of the patient condition at the time of admission. There is also no linkage from HES to microbiology data or outbreak surveillance systems, so we were unable to account for impact of local outbreaks. For the CDI versus no CDI analysis, we matched on year of admission, and for the recurrent CDI versus CDI analysis, we adjusted for year of admission, in an attempt to mitigate the impact of large national outbreaks or important temporal trends. Lastly, in the absence of objective laboratory or pathology evidence to link CDI to cause of death, it was not possible to estimate the proportion of deaths attributable to CDI; given this, we assessed all-cause mortality up to 12 months to capture both short and longer term, and direct and indirect effects of CDI.

In summary, this study draws on a substantial body of data from routine clinical practice to demonstrate that patients who have CDI during their hospital stay have higher mortality rates than patients who do not. Among patients who have HA-CDI, those with recurrent CDI are at greater risk of complications or death than those with non-recurrent CDI. Our data provide a comprehensive picture of the impact of CDI in England, and highlight the importance of preventing and managing initial and recurrent episodes of CDI.

# Author declarations

## Acknowledgements

This study was funded by Astellas Pharma Inc. We wish to thank Reiner Tretter, statistician at Astellas Pharma Inc. at the time of this study, for his contribution to the analysis and Iona Easthope, DPhil, of Cello Health MedErgy for medical writing services.

Previous presentations: oral presentation at the 25th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), 25−28th April 2015, Copenhagen, Denmark; e-poster at the 27th ECCMID, 22–25th April 2017, Vienna, Austria.

**Author contributions**

DAE, TMT, NA, DD, NF and AK were involved in the concept and design of the study.

TMT, NA, DD, AG and AK were involved in the acquisition, analysis and/or interpretation of the data.

All authors participated in drafting the manuscript and its critical revisions for important intellectual content.

All authors have approved the final submitted article.

## Disclosures

DAE has received fees for conference attendance from Astellas Pharma, Eumedica, Pfizer, Gilead and MSD, and for consultancy work from Cardiome.

TMT and DD are full-time employees of CPRD, which provides contract research services and which received payment from Astellas Pharma for work on the study.

NA and AG were full-time employees of Astellas Pharma at the time of the study.

AK was a full-time employee of Astellas Pharma at the time of the study, and has patents WO2015169451 A1 and EP17167541.6 pending, which are licenced to Astellas Pharma.

## Funding source

This research study and medical writing services were funded by Astellas Pharma Inc.

Astellas Pharma Inc. was involved in the study design; the collection, analysis and interpretation of data; the writing of the report; and the decision to submit the article for publication.

# References

[1] Zhu D, Sorg JA, Sun X. *Clostridioides difficile* biology: sporulation, germination, and corresponding therapies for *C. difficile* infection. Front Cell Infect Microbiol 2018;8:1–29. doi:10.3389/fcimb.2018.00029.

[2] Schäffler H, Breitruck A. *Clostridium difficile*  – from colonization to infection. Front Microbiol 2018;9:646. doi:10.3389/fmicb.2018.00646.

[3] Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, McDonald LC, et al. Clinical practice guidelines for *Clostridium difficile* infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol 2010;31:431–55. doi:10.1086/651706.

[4] Haines CF, Moore RD, Bartlett JG, Sears CL, Cosgrove SE, Carroll K, et al. *Clostridium difficile* in a HIV-infected cohort: incidence, risk factors, and clinical outcomes. AIDS 2013;27:2799–807. doi:10.1097/01.aids.0000432450.37863.e9.

[5] Dial S, Delaney JAC, Barkun AN, Suissa S. Use of gastric acid-suppressive agents and the risk of community-acquired *Clostridium difficile*-associated disease. J Am Med Assoc 2005;294:2989–95. doi:10.1001/jama.294.23.2989.

[6] Asha NJ, Tompkins D, Wilcox MH. Comparative analysis of prevalence, risk factors, and molecular epidemiology of antibiotic-associated diarrhea due to *Clostridium difficile*, *Clostridium perfringens*, and *Staphylococcus aureus*. J Clin Microbiol 2006;44:2785–91. doi:10.1128/JCM.00165-06.

[7] Howell MD, Novack V, Grgurich P, Soulliard D, Novack L, Pencina M, et al. Iatrogenic gastric acid suppression and the risk of nosocomial *Clostridium difficile* infection. Arch Intern Med 2010;170:784–90. doi:10.1001/archinternmed.2010.89.

[8] Lo Vecchio A, Zacur GM. *Clostridium difficile* infection: An update on epidemiology, risk factors, and therapeutic options. Curr Opin Gastroenterol 2012;28:1–9. doi:10.1097/MOG.0b013e32834bc9a9.

[9] Bouza E. Consequences of *Clostridium difficile* infection: understanding the healthcare burden. Clin Microbiol Infect 2012;18 Suppl 6:5–12. doi:10.1111/1469-0691.12064.

[10] Wiegand PN, Nathwani D, Wilcox MH, Stephens J, Shelbaya A, Haider S. Clinical and economic burden of *Clostridium difficile* infection in Europe: a systematic review of healthcare-facility-acquired infection. J Hosp Infect 2012;81:1–14. doi:10.1016/j.jhin.2012.02.004.

[11] Bartlett JG, Gerding DN. Clinical recognition and diagnosis of *Clostridium difficile* infection. Clin Infect Dis 2008;46:S12–8. doi:10.1086/521863.

[12] Chakra CNA, Pepin J, Sirard S, Valiquette L. Risk factors for recurrence, complications and mortality in *Clostridium difficile* infection: a systematic review. PLoS One 2014;9:e98400. doi:10.1371/journal.pone.0107420.

[13] McDonald LC, Gerding DN, Johnson S, Bakken JS, Carroll KC, Coffin SE, et al. Clinical practice guidelines for *Clostridium difficile* infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis 2018;66:e1–48. doi:10.1093/cid/cix1085.

[14] Olsen MA, Stwalley D, Demont C, Dubberke ER. *Clostridium difficile* infection increases acute and chronic morbidity and mortality. Infect Control Hosp Epidemiol 2019;40:65–71. doi:10.1017/ice.2018.280.

[15] Bauer MP, Notermans DW, van Benthem BH, Brazier JS, Wilcox MH, Rupnik DL, et al. *Clostridium difficile* infection in Europe: a hospital-based survey. Lancet 2011;377:63–73. doi:http://dx.doi.org/10.1016/S0140-6736(10)61266-4.

[16] Barbut F, Bouée S, Longepierre L, Goldberg M, Bensoussan C, Levy-Bachelot L. Excess mortality between 2007 and 2014 among patients with *Clostridium difficile* infection: a French health insurance database analysis. J Hosp Infect 2018;98:21–8. doi:10.1016/j.jhin.2017.07.006.

[17] Banks A, Moore EK, Bishop J, Coia JE, Brown D, Mather H, et al. Trends in mortality following *Clostridium difficile* infection in Scotland, 2010-2016: a retrospective cohort and case-control study. J Hosp Infect 2018;100:133–41. doi:10.1016/j.jhin.2018.07.023.

[18] Reacher M, Verlander NQ, Roddick I, Trundle C, Brown N, Farrington M, et al. Excess mortality attributable to *Clostridium difficile* and risk factors for infection in an historic cohort of hospitalised patients followed up in the United Kingdom death register. PLoS One 2016;11:1–23. doi:10.1371/journal.pone.0149983.

[19] Kuntz JL, Baker JM, Kipnis P, Li SX, Liu V, Xie Y, et al. Utilization of health services among adults with recurrent *Clostridium difficile* infection: a 12-year population-based study. Infect Control Hosp Epidemiol 2017;38:45–52. doi:10.1017/ice.2016.232.

[20] Shah DN, Aitken SL, Barragan LF, Bozorgui S, Goddu S, Navarro ME, et al. Economic burden of primary compared with recurrent *Clostridium difficile* infection in hospitalized patients: a prospective cohort study. J Hosp Infect 2016;93:286–9. doi:10.1016/j.jhin.2016.04.004.

[21] Olsen MA, Yan Y, Reske KA, Zilberberg MD, Dubberke ER. Recurrent *Clostridium difficile* infection is associated with increased mortality. Clin Microbiol Infect 2015;21:164–70. doi:10.1016/j.cmi.2014.08.017.

[22] Reveles KR, Lawson KA, Mortensen EM, Pugh MJ V., Koeller JM, Argamany JR, et al. National epidemiology of initial and recurrent *Clostridium difficile* infection in the Veterans Health Administration from 2003 to 2014. PLoS One 2017;12:1–14. doi:10.1371/journal.pone.0189227.

[23] Khanna S, Gupta A, Baddour LM, Pardi DS. Epidemiology, outcomes, and predictors of mortality in hospitalized adults with *Clostridium difficile* infection. Intern Emerg Med 2016;11:657–65. doi:10.1007/s11739-015-1366-6.

[24] Esteban-Vasallo MD, de Miguel-Díez J, López-de-Andrés A, Hernández-Barrera V, Jiménez-García R. *Clostridium difficile*-related hospitalizations and risk factors for in-hospital mortality in Spain between 2001 and 2015. J Hosp Infect 2019;102:148–56. doi:10.1016/j.jhin.2018.09.006.

[25] Sammons JS, Localio R, Xiao R, Coffin SE, Zaoutis T. *Clostridium difficile* infection is associated with increased risk of death and prolonged hospitalization in children. Clin Infect Dis 2013;57:1–8. doi:10.1093/cid/cit155.

[26] UK National Health Service. Hospital Episode Statistics 2019. https://digital.nhs.uk/data-and-information/data-tools-and-services/data-services/hospital-episode-statistics (accessed March 12, 2020).

[27] UK Statistics Authority. Office for National Statistics n.d. https://www.ons.gov.uk/ (accessed March 12, 2020).

[28] UK Government. English indices of deprivation 2019. https://www.gov.uk/government/statistics/english-indices-of-deprivation-2019 (accessed March 12, 2020).

[29] UK National Health Service. Hospital Episode Statistics (HES) Analysis Guide 2019. https://digital.nhs.uk/binaries/content/assets/website-assets/data-and-information/data-tools-and-services/data-services/hospital-episode-statistics/hes\_analysis\_guide\_september\_2018-v1.1.pdf (accessed March 12, 2020).

[30] Jen M-H, Saxena S, Bottle A, Pollok R, Holmes A, Aylin P. Assessment of administrative data for evaluating the shifting acquisition of *Clostridium difficile* infection in England. J Hosp Infect 2012;80:229–37. doi:10.1016/j.jhin.2012.01.001.

[31] Hensgens MPM, Goorhuis A, Dekkers OM, Van Benthem BHB, Kuijper EJ. All-cause and disease-specific mortality in hospitalized patients with *Clostridium difficile* infection: a multicenter cohort study. Clin Infect Dis 2013;56:1108–16. doi:10.1093/cid/cis1209.

[32] Escobar GJ, Baker JM, Li SX, Xie Y, Kipnis P. Clinical and economic burden of recurrent *Clostridium difficile* infections - a 10-year retrospective large database analysis. 54th Intersci. Conf. Antimicrob. Agents Chemother., 2014.

[33] Shintani AK, Girard TD, Eden SK, Arbogast PG, Moons KGM, Ely EW. Immortal time bias in critical care research: application of time-varying Cox regression for observational cohort studies. Crit Care Med 2009;37:2939–45. doi:10.1097/CCM.0b013e3181b7fbbb.

[34] Delgado A, Reveles IA, Cabello FT, Reveles KR. Poorer outcomes among cancer patients diagnosed with *Clostridium difficile* infections in United States community hospitals. BMC Infect Dis 2017;17:448. doi:10.1186/s12879-017-2553-z.

[35] Forster AJ, Taljaard M, Oake N, Wilson K, Roth V, van Walraven C. The effect of hospital-acquired infection with *Clostridium difficile* on length of stay in hospital. CMAJ 2012;184:37–42. doi:10.1503/cmaj.110543.

[36] Yasunaga H, Horiguchi H, Hashimoto H, Matsuda S, Fushimi K. The burden of *Clostridium difficile*-associated disease following digestive tract surgery in Japan. J Hosp Infect 2012;82:175–80. doi:10.1016/j.jhin.2012.07.023.

[37] Goldenberg SD, Brown S, Edwards L, Gnanarajah D, Howard P, Jenkins D, et al. The impact of the introduction of fidaxomicin on the management of *Clostridium difficile* infection in seven NHS secondary care hospitals in England: a series of local service evaluations. Eur J Clin Microbiol Infect Dis 2016;35:251–9. doi:10.1007/s10096-015-2538-z.

[38] Louie TJ, Miller MA, Mullane KM, Weiss K, Lentnek A, Golan Y, et al. Fidaxomicin versus vancomycin for *Clostridium difficile* infection. N Engl J Med 2011;364:422–31. doi:10.1056/NEJMoa0910812.

[39] Cornely OA, Crook DW, Esposito R, Poirier A, Somero MS, Weiss K, et al. Fidaxomicin versus vancomycin for infection with *Clostridium difficile* in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. Lancet Infect Dis 2012;12:281–9. doi:10.1016/S1473-3099(11)70374-7.

[40] Stevens V, Dumyati G, Fine LS, Fisher SG, van Wijngaarden E. Cumulative antibiotic exposures over time and the risk of *Clostridium difficile* infection. Clin Infect Dis 2011;53:42–8. doi:10.1093/cid/cir301.

[41] Stevens V, Concannon C, van Wijngaarden E, McGregor J. Validation of the chronic disease score-infectious disease (CDS-ID) for the prediction of hospital-associated *Clostridium difficile* infection (CDI) within a retrospective cohort. BMC Infect Dis 2013;13:1–8.

[42] Khanafer N, Vanhems P, Barbut F, Luxemburger C. Factors associated with *Clostridium difficile* infection: a nested case-control study in a three year prospective cohort. Anaerobe 2017;44:117–23. doi:10.1016/j.anaerobe.2017.03.003.

[43] Ingle M, Deshmukh A, Desai D, Abraham P, Joshi A, Rodrigues C, et al. Prevalence and clinical course of *Clostridium difficile* infection in a tertiary-care hospital: a retrospective analysis. Indian J Gastroenterol 2011;30:89–93. doi:10.1007/s12664-011-0097-5.

[44] Šuljagić V, Miljković I, Starčević S, Stepić N, Kostić Z, Jovanović D, et al. Risk factors for *Clostridium difficile* infection in surgical patients hospitalized in a tertiary hospital in Belgrade, Serbia: a case-control study. Antimicrob Resist Infect Control 2017;6. doi:10.1186/s13756-017-0188-x.

[45] Chung MS, Kim J, Kang JO, Pai H. Impact of malignancy on *Clostridium difficile* infection. Eur J Clin Microbiol Infect Dis 2016;35:1771–6. doi:10.1007/s10096-016-2725-6.

[46] Phatharacharukul P, Thongprayoon C, Cheungpasitporn W, Edmonds PJ, Mahaparn P, Bruminhent J. The risks of incident and recurrent *Clostridium difficile*-associated diarrhea in chronic kidney disease and end-stage kidney disease patients: a systematic review and meta-analysis. Dig Dis Sci 2015;60:2913–22. doi:10.1007/s10620-015-3714-9.

[47] Abdelfatah M, Nayfe R, Nijim A, Enriquez K, Ali E, Watkins RR, et al. Factors predicting recurrence of *Clostridium difficile* infection (CDI) in hospitalized patients: retrospective study of more than 2000 patients. J Investig Med 2015;63:747–51. doi:10.1097/JIM.0000000000000188.

[48] Mathews SN, Lamm R, Yang J, Park J, Tzimas D, Buscaglia JM, et al. Factors associated with health care utilization of recurrent *Clostridium difficile* infection in New York State. J Clin Gastroenterol 2019;53:298–303. doi:10.1097/MCG.0000000000001022.

[49] Gómez S, Chaves F, Orellana MA. Clinical, epidemiological and microbiological characteristics of relapse and re-infection in *Clostridium difficile* infection. Anaerobe 2017;48:147–51. doi:10.1016/j.anaerobe.2017.08.012.

[50] Jones G, Taright N, Boelle PY, Marty J, Lalande V, Eckert C, et al. Accuracy of ICD-10 codes for surveillance of clostridium difficile infections, France. Emerg Infect Dis 2012;18:979–81. doi:10.3201/eid1806.111188.

[51] Redondo-González O, Tenías JM, Arias Á, Lucendo AJ. Validity and Reliability of Administrative Coded Data for the Identification of Hospital-Acquired Infections: An Updated Systematic Review with Meta-Analysis and Meta-Regression Analysis. Health Serv Res 2018;53:1919–56. doi:10.1111/1475-6773.12691.

# Tables

**Table I.** Baseline characteristics of patients with HA-CDI and no CDI, and patients with recurrent and non-recurrent CDI

|  | **HA-CDI and no CDI cohorta** | **Recurrent CDI and non-recurrent CDI cohortb** |
| --- | --- | --- |
|  | **HA-CDI****(N=6862)** | **No CDI****(N=13 724)** | **Total (N=20 586)** | ***P*-value** | **Recurrent CDI (N=1140)** | **Non-recurrent CDI (N=5722)** | **Total (N=6862)** | ***P*-value** |
| **Baseline characteristics** |  |  |  |  |  |  |  |  |
| Age in years, median (IQR)  | 81.0 (72.0–87.0) | 81.0 (71.0–87.0) | 81.0 (71.0–87.0) | 0.092 | 81.0 (72.0–87.0) | 81.0 (72.0–87.0) | 81.0 (72.0–87.0) | 0.688 |
| Female, n (%) | 4047 (59.0) | 8094 (59.0) | 12 141 (59.0) | 1.000c | 678 (59.5)  | 3369 (58.9)  | 4047 (59.0)  | 0.709 |
| BMI |  |  |  |  |  |  |  |  |
| Median (IQR) | 25.4 (22.2–29.1) | 25.4 (22.5–28.9) | 25.4 (22.4–28.9) | 0.381 | 25.5 (22.1–29.1)  | 25.4 (22.2–29.2)  | 25.4 (22.2–29.1)  | 0.901  |
| Missing | 1382 (20.1%)  | 2761 (20.1%)  | 4143 (20.1%)  |  |  |  |  |  |
| Smoking status |  |  |  | <0.001 |  |  |  | 0.513 |
| Non-smoker | 2659 (38.7) | 5772 (42.1)  | 8431 (41.0)  |  | 420 (36.8)  | 2239 (39.1)  | 2659 (38.7) |  |
| Ex-smoker | 2679 (39.0)  | 4917 (35.8)  | 7596 (36.9)  |  | 468 (41.1) | 2,211 (38.6) | 2,679 (39.0) |  |
| Smoker | 1136 (16.6)  | 2173 (15.8)  | 3309 (16.1)  |  | 205 (18.0)  | 931 (16.3)  | 1,136 (16.6)  |  |
| Unknown | 388 (5.7)  | 862 (6.3)  | 1250 (6.1)  |  | 47 (4.1)  | 341 (6.0)  | 388 (5.7)  |  |
| Drinking status |  |  |  | <0.001  |  |  |  | 0.513  |
| Non-drinker | 1010 (14.7)  | 1852 (13.5)  | 2862 (13.9)  |  | 163 (14.3)  | 847 (14.8)  | 1010 (14.7)  |  |
| Ex-drinker | 769 (11.2)  | 1321 (9.6)  | 2090 (10.2)  |  | 122 (10.7)  | 647 (11.3)  | 769 (11.2)  |  |
| Drinker | 3867 (56.4)  | 8005 (58.3)  | 11 872 (57.7)  |  | 667 (58.5)  | 3200 (55.9)  | 3867 (56.4)  |  |
| Missing | 1216 (17.7)  | 2546 (18.6)  | 3762 (18.3)  |  | 188 (16.5)  | 1028 (18.0)  | 1216 (17.7) |  |
| Socioeconomic deprivation leveld |  |  |  | <0.001 |  |  |  | 0.704 |
| 1 | 1200 (17.5)  | 2787 (20.3)  | 3987 (19.4)  |  | 210 (18.4)  | 990 (17.3)  | 1200 (17.5)  |  |
| 2 | 1590 (23.2)  | 3284 (23.9)  | 4874 (23.7)  |  | 262 (23.0)  | 1328 (23.2)  | 1590 (23.2) |  |
| 3 | 1396 (20.3)  | 2892 (21.1)  | 4288 (20.8)  |  | 215 (18.9)  | 1181 (20.6)  | 1396 (20.3) |  |
| 4 | 1416 (20.6)  | 2586 (18.8)  | 4002 (19.4)  |  | 237 (20.8)  | 1179 (20.6)  | 1416 (20.6) |  |
| 5 | 1249 (18.2)  | 2151 (15.7)  | 3400 (16.5)  |  | 215 (18.9)  | 1034 (18.1)  | 1249 (18.2) |  |
| Missing | 11 (0.2)  | 24 (0.2)  | 35 (0.2)  |  | 1 (<0.1)  | 10 (0.2)  | 11 (0.2) |  |
| **Current or prior comorbidities** |  |  |  |  |  |  |  |  |
| Diabetes mellituse, n (%)  | 1369 (20.0)  | 1979 (14.4)  | 3348 (16.3)  | <0.001  | 247 (21.7)  | 1130 (19.7)  | 1377 (20.1)  | 0.140  |
| Hypertensione  | 5036 (73.4)  | 9172 (66.8)  | 14 208 (69.0)  | <0.001  | 864 (75.8)  | 4172 (72.9)  | 5036 (73.4)  | 0.045  |
| Inflammatory bowel diseasee  | 214 (3.1) | 81 (0.6) | 295 (1.4) | <0.001 | 44 (3.9)  | 176 (3.1)  | 220 (3.2)  | 0.170  |
| Renal diseasee  | 2386 (34.8) | 3163 (23.0) | 5549 (27.0) | <0.001 | 440 (38.6)  | 1993 (34.8)  | 2433 (35.5)  | 0.015  |
| Cerebrovascular accidente  | 1910 (27.8) | 3249 (23.7) | 5159 (25.1) | <0.001 | 349 (30.6)  | 1625 (28.4)  | 1974 (28.8)  | 0.131  |
| Moderate-to-severe liver diseasee  | 158 (2.3) | 88 (0.6) | 246 (1.2) | <0.001 | 40 (3.5)  | 132 (2.3)  | 172 (2.5)  | 0.018  |
| Peripheral vascular diseasee  | 1076 (15.7) | 1418 (10.3) | 2494 (12.1) | <0.001 | 191 (16.8)  | 899 (15.7)  | 1090 (15.9)  | 0.379  |
| Dementiae | 850 (12.4) | 1694 (12.3) | 2544 (12.4) | 0.928 | 125 (11.0) | 758 (13.2) | 883 (12.9) | 0.036 |
| Malignant cancer ≤5 years previously, n (%) | 1485 (21.6) | 1781 (13.0) | 3266 (15.9) | <0.001 | 213 (18.7)  | 1299 (22.7)  | 1512 (22.0)  | 0.003  |
| Transplantation ≤24 months previously, n (%) | 87 (1.3) | 15 (0.1) | 102 (0.5) | <0.001 | 14 (1.2)  | 75 (1.3)  | 89 (1.3)  | 0.822  |
| **Medication prescriptions ≤90 days previously** |  |  |  |  |  |
| Any antibiotic, n (%) | 2749 (40.1) | 3961 (28.9) | 6710 (32.6) | <0.001 | 478 (41.9)  | 2254 (39.4)  | 2732 (39.8)  | 0.110  |
| Lipid-lowering drugs, n (%) | 1904 (27.7) | 3492 (25.4) | 5396 (26.2) | <0.001 | 344 (30.2)  | 1547 (27.0)  | 1891 (27.6)  | 0.030  |
| Immunosuppressants excluding hydrocortisone and prednisolone, n (%) | 59 (0.9) | 27 (0.2) | 86 (0.4) | <0.001 | 9 (0.8)  | 50 (0.9)  | 59 (0.9)  | 0.778  |
| Hydrocortisone and/or prednisolone, n (%) | 788 (11.5) | 1023 (7.5) | 1811 (8.8) | <0.001 | 137 (12.0)  | 649 (11.3)  | 786 (11.5)  | 0.513  |
| Proton-pump inhibitors, n (%) | 2285 (33.3)  | 2806 (20.4)  | 5091 (24.7)  | <0.001  | 382 (33.5)  | 1888 (33.0)  | 2270 (33.1)  | 0.737  |
| Glucocorticoids, n (%) | 804 (11.7)  | 1041 (7.6)  | 1845 (9.0)  | <0.001  | 139 (12.2)  | 663 (11.6)  | 802 (11.7)  | 0.561  |
| **Health service use ≤12 months previously** |  |  |  |  |  |
| GP consultations, mean (SD)  | 17.2 (15.4)  | 12.3 (11.7)  | 13.9 (13.2)  | <0.001  | 17.8 (15.8) | 17.1 (15.4) | 17.3 (15.4) | 0.537 |
| ≥2 prior hospitalizations | 2926 (42.6)  | 2124 (15.5)  | 5050 (24.5)  | <0.001 | 574 (50.4%)  | 2809 (49.1%)  | 3383 (49.3%)  | 0.032  |
| **Index hospitalization** |  |  |  |  |  |  |  |  |
| Duration of hospital stay, median (IQR) | 28.0 (15.0–50.0)  | 6.0 (1.0–15.0)  | 11.0 (3.0–28.0)  | <0.001 | 39.0 (24.0–62.0) | 26.0 (14.0–47.0) | 28.0 (15.0–50.0) | <0.001  |
| Emergency admission, n (%) | 5832 (85.0)  | 11 664 (85.0)  | 17 496 (85.0)  | 1.000c | 997 (87.5)  | 4835 (84.5)  | 5832 (85.0)  | 0.011  |
| Augmented/intensive caref, n (%) | 234 (3.4)  | 119 (0.9)  | 353 (1.7)  | <0.001  | 44 (3.9)  | 229 (4.0)  | 273 (4.0)  | 0.822  |

aCharacteristics were assessed for the specified duration prior to index hospital admission. **b**Characteristics were assessed for the specified period prior to the index HA-CDI episode. cPatients with no CDI were matched to those with HA-CDI for this parameter. dGrouping based on Index of Multiple Deprivation scores, with 1 being the least deprived and 5 the most deprived. eAt any time previously. fAssessed from admission to index date. CDI, *Clostridioides difficile* infection; HA, hospital-associated

## Table II. Incidence of death or complications in patients with CDI

|  |  |  |  |
| --- | --- | --- | --- |
|  |  | **HA-CDI versus no CDI** | **Recurrent CDI versus non-recurrent CDI** |
| **Outcome** | **Time to outcome** | **HA-CDI** **(N=6,862)** | **No CDI** **(N=13,724)** | **p-value** | **Recurrent CDI (N=1,140)** | **Non-recurrent CDI (N=5,722)** | **p-value** |
| Deatha, n (%) | ≤30 days | 1117 (16.3) | 2041 (14.9) | 0.008 | 87 (7.6) | 1102 (19.3) | <0.001 |
| ≤90 days | 2535 (36.9) | 3094 (22.5) | <0.001 | 381 (33.4) | 2164 (37.8) | 0.005 |
| ≤180 days | 3076 (44.8) | 3613 (26.3) | <0.001 | 492 (43.2) | 2494 (43.6) | 0.790 |
| ≤365 days | 3427 (49.9) | 4146 (30.2) | <0.001 | 564 (49.5) | 2737 (47.8) | 0.311 |
| Complicationsb, n (%) | ≤30 days | 1227 (17.9) | 1009 (7.4) | <0.001 | 183 (16.1) | 868 (15.2) | 0.450 |
| ≤90 days | 1353 (19.7) | 1096 (8.0) | <0.001 | 226 (19.8) | 940 (16.4) | 0.005 |
| ≤180 days | 1436 (20.9) | 1164 (8.5) | <0.001 | 241 (21.1) | 996 (17.4) | 0.003 |
| ≤365 days | 1486 (21.7) | 1240 (9.0) | <0.001 | 249 (21.8) | 1036 (18.1) | 0.003 |
| Complicationsb or deatha, n (%) | ≤30 days | 2032 (29.6) | 2639 (19.2) | <0.001 | 247 (21.7) | 1690 (29.5) | <0.001 |
| ≤90 days | 3251 (47.4) | 3620 (26.4) | <0.001 | 520 (45.6) | 2628 (45.9) | 0.846 |
| ≤180 days | 3742 (54.5) | 4137 (30.1) | <0.001 | 615 (53.9) | 2943 (51.4) | 0.121 |
| ≤365 days | 4055 (59.1) | 4668 (34.0) | <0.001 | 682 (59.8) | 3173 (55.5) | 0.007 |

Follow up was from the start of the initial hospital care episode. CDI, *Clostridioides difficile* infection; HA, hospital-associated. aAscertained using death registration recorded in Office of National Statistics mortality data. bEvaluated using primary care (CPRD GOLD), hospital (HES) and Office of National Statistics mortality data. Complications included ulcerative pancolitis, megacolon, intestinal perforation, toxic gastroenteritis/colitis, colectomy, renal failure and sepsis (**Table A.I**, online supplementary information)

**Table III** Twelve-month risk of death or complications for patients with HA-CDI versus no CDI and for recurrent CDI versus non-recurrent CDI

|  |
| --- |
| **HA-CDI versus no CDI** |
|  |  |  |  | **Death**a | **Complications**b | **Complications**b **or death**a |
| **Model** | **CDI covariate specification** | **Index date of CDI** | **Start of follow up**  | **Unadjusted HR (95% CI)** | **Adjusted HR (95% CI)** | **Unadjusted HR (95% CI)** | **Adjusted HR (95% CI)** | **Unadjusted HR (95% CI)** | **Adjusted HR (95% CI)** |
| 1 | Time-dependent  | Start of CDI episode | Hospital admission | 1.96 (1.87–2.06)\* | 1.77 (1.67–1.87)\* | 1.80 (1.58–2.03)\* | 1.66 (1.46–1.88)\* | 1.99 (1.89–2.08)\* | 1.75 (1.65–1.86)\* |
| 2 | Time-fixed  | Start of CDI episode | Start of CDI/selected hospital care episode | 1.77 (1.69–1.85)\* | 1.55 (1.47–1.64)\* | 3.27 (3.00–3.56)\* | 3.36 (3.06–3.68)\* | 2.05 (1.96–2.14)\* | 1.88 (1.78–1.98)\* |
| **Recurrent CDI versus non-recurrent CDI** |
|  |  |  |  | **Death**a | **Complications**b | **Complications**b **or death**a |
| **Model** | **CDI specification** | **Index date of recurrent CDI** | **Start of follow up**  | **Unadjusted HR (95% CI)** | **Adjusted HR (95% CI)** | **Unadjusted HR (95% CI)** | **Adjusted HR (95% CI)** | **Unadjusted HR (95% CI)** | **Adjusted HR (95% CI)** |
| 3 | Time-dependent  | Start of recurrent episode | Episode start of the index CDI  | 1.37 (1.25–1.50)\* | 1.32 (1.20–1.45)\* | 1.37 (1.02–1.85)\* | 1.37 (1.01–1.84)\* | 1.40 (1.26–1.54)\* | 1.36 (1.22–1.50)\* |
| 4 | Time-dependent  | Start of recurrent episode | Day 13 (start of recurrence risk window)c  | 1.37 (1.25–1.50)\* | 1.34 (1.22–1.47)\* | 1.37 (1.02–1.85)\* | 1.35 (1.00–1.83)\* | 1.40 (1.26–1.54)\* | 1.36 (1.23–1.50)\* |
| 5 | Time-fixed  | Final CDI statusd | Day 57 (end of the recurrence risk window)c  | 1.45 (1.27–1.64)\* | 1.40 (1.23–1.59)\* | 1.39 (0.95–2.02) | 1.34 (0.91–1.95) | 1.50 (1.31–1.71)\* | 1.46 (1.27–1.67)\* |
| 6 | Time-fixed  | Final CDI statusd | Episode start of the index CDI  | 0.91 (0.83–1.00)\* | 0.88 (0.80–0.96)\* | 1.18 (1.03–1.36)\* | 1.17 (1.02–1.34)\* | 1.01 (0.93–1.10) | 0.99 (0.91–1.08) |

CDI, *Clostridioides difficile* infection; HA, hospital-associated; HR, hazard ratio. Recurrent CDI was defined as a second CDI episode diagnosed on Days 13−56. aAscertained using death registration recorded in Office of National Statistics mortality data. bEvaluated using primary care (CPRD GOLD), hospital (HES) and Office of National Statistics mortality data. Complications included ulcerative pancolitis, megacolon, intestinal perforation, toxic gastroenteritis/colitis, colectomy, renal failure and sepsis (**Table A.I**, online supplementary information). cAs evaluated from the date of index CDI. dDefined as ever having a diagnosis of CDI (yes or no) during the study period. \*p<0.05 for comparison

# Figures

## Figure 1. Selection of cases with HA-CDI recorded in the first or second episode of hospital care



aPatients are considered acceptable by the CPRD based on 15-point criteria that excludes patients with non-continuous follow up, or patients with poor data recording that raises suspicion as to the validity of those patients’ records. CDI, *Clostridioides difficile* infection; CPRD, Clinical Practice Research Datalink; HA, hospital-associated; HES, Hospital Episode Statistics; UTS, up-to-standard. Grey boxes indicate patients excluded from the dataset.

## Figure 2. Twelve-month mortality, assessed from the start of the CDI recurrence window, among patients with recurrent and non-recurrent CDI



CDI, *Clostridioides difficile* infection. Recurrent CDI was defined as a second CDI episode documented on days 13−56 inclusive. Time to death was assessed from the start of the CDI recurrence window at day 13. The date of recurrence was defined as the start of the hospital episode in which the recurrent CDI episode was identified.

# Figure legends

**Figure 1**. Selection of cases with HA-CDI recorded in the first or second episode of hospital care.

aPatients are considered acceptable by the CPRD based on 15-point criteria that excludes patients with non-continuous follow up, or patients with poor data recording that raises suspicion as to the validity of those patients’ records. CDI, *Clostridioides difficile* infection; CPRD, Clinical Practice Research Datalink; HA, hospital-associated; HES, Hospital Episode Statistics; UTS, up-to-standard. Grey boxes indicate patients excluded from the dataset.

**Figure 2.** Twelve-month mortality, assessed from the start of the CDI recurrence window, among patients with recurrent and non-recurrent CDI.

CDI, *Clostridioides difficile* infection. Recurrent CDI was defined as a second CDI episode documented on Days 13−56 inclusive. Time to death was assessed from the start of the CDI recurrence window at Day 13. The date of recurrence was defined as the start of the hospital episode in which the recurrent CDI episode was identified.